The most abundant protein on Earth is RuBisCO, the enzyme that powers photosynthesis. It is also, for food scientists, a notoriously difficult material to work with. Alfa-Ruby, a St. Louis startup founded in 2025, is building its entire business on the premise that it can extract this protein from fresh alfalfa leaves at a commercial scale, delivering an ingredient that performs like animal protein without the allergens or the cost [Alfa-Ruby, Unknown]. The company’s wedge is a B2B ingredient supplier, targeting food and beverage manufacturers with a plant-based protein isolate designed to match whey and egg in solubility, emulsification, and gelation [Alfa-Ruby, Unknown]. It is a classic infrastructure play, betting that a better, cheaper, and cleaner input can reshape the products built on top of it.
The alfalfa wedge
Alfa-Ruby’s process starts with a field, not a fermenter. The company sources fresh alfalfa leaves, running them through a proprietary extraction method to isolate the RuBisCO protein. The choice of feedstock is strategic. Alfalfa is a high-yield, nitrogen-fixing cover crop already grown at massive scale for animal feed. Founder Chris Pratt, a fourth-generation farmer, brings three decades of experience with the crop to the venture [Alfa-Ruby, Unknown]. The company claims its end-to-end field-to-ingredient process preserves protein quality and yield, resulting in a product with high digestibility and a balanced amino-acid profile [Alfa-Ruby, Unknown]. For manufacturers, the promised tradeoff is straightforward: swap in a plant protein that behaves like an animal one, gain a sustainability story, and remove a major allergen label, all at a lower unit cost [Arch Grants, October 2025].
A crowded field of leaf proteins
The bet is not happening in a vacuum. Alfa-Ruby is entering a category where several well-funded competitors are racing to commercialize leaf-derived proteins, each with its own technical approach and target market.
| Company | Primary Feedstock | Notable Traction / Funding |
|---|---|---|
| Plantible Foods | Duckweed | Raised a $23.5M Series A in 2023 [Crunchbase]. |
| Leaft Foods | New Zealand pasture grasses | Secured a $15M Series A in 2022 [Crunchbase]. |
| Rubisco Foods | Alfalfa (via sugar beet leaves) | A Dutch company with an established pilot plant. |
| Fudi Protein | Moringa | Early-stage, focused on the Asian market. |
| Alfa-Ruby | Alfalfa | $75,000 Arch Grants award in 2025 [Signalbase, October 2025]. |
Alfa-Ruby’s early position is defined by its modest, non-dilutive grant funding and its deep integration into the St. Louis agtech ecosystem, which includes connections to 39 North, BioGenerator Ventures, and the Donald Danforth Plant Science Center [Startland News, October 2025]. The company lists a small team of five, including a CTO and directors for strategy and marketing, suggesting a focus on both technical development and early commercial outreach [Alfa-Ruby, Unknown].
The scale-up equation
The technical claims are compelling on paper, but the path from a grant-funded prototype to a commodity-scale ingredient supplier is steep. The core challenges are not scientific novelty but industrial reliability and unit economics. Every step in the supply chain, from leaf harvesting and rapid processing to protein purification and drying, must be optimized for consistency and cost. A single batch demonstrating perfect gelation is a lab result; delivering ten thousand metric tons of standardized powder that behaves identically in a factory vat is a manufacturing feat. The company has not yet disclosed commercial customers or pilot partners, which is the next critical signal for its technology [Good Food Institute, August 2026].
The competitive landscape adds pressure. Larger, better-funded players are moving down the cost curve, and ingredient buyers are notoriously conservative, requiring extensive testing and qualification before reformulating a product. Alfa-Ruby’s advantages in its current form are its founder’s agricultural expertise and a potentially streamlined process using a familiar crop. To convert those into a business, the company will need to prove three things in its next phase:
- Extraction yield. The grams of pure, functional protein isolated per ton of fresh alfalfa leaves.
- Process cost. The all-in cost per kilogram of isolate, which must undercut whey protein concentrate to be compelling.
- Functional parity. Consistent performance in real-world food applications like protein bars, shakes, and meat alternatives.
Success on these fronts would position Alfa-Ruby not as another alternative protein company, but as a specialized industrial ingredient producer. The risk is that the complexity of scaling a biological extraction process consumes capital and time faster than the market’s patience, a common story in agtech. For now, the company has secured a foothold and a clear technical thesis. The next eighteen months will be about moving from the field trial to the factory floor.
Sources
- [Alfa-Ruby, Unknown] Company website and product pages | https://alfa-ruby.com/
- [Arch Grants, October 2025] Alfa-Ruby Inc. company profile | https://archgrants.org/companies/alfa-ruby-inc/
- [Signalbase, October 2025] Alfa-Ruby Inc. Secures $75,000 Grant Funding | https://www.trysignalbase.com/news/funding/alfa-ruby-inc-secures-75000-grant-funding
- [Startland News, October 2025] Arch Grants taps homegrown founders, Missouri startup … | https://startlandnews.com/2025/10/arch-grants-missouri/
- [Good Food Institute, August 2026] Alfa-Ruby ecosystem listing | https://ecosystem.gfi.org/company/alfa-ruby/